| 10000-8 | R wave duration in lead AVR |
| 10001-6 | R wave duration in lead I |
| 10002-4 | R wave duration in lead II |
| 10003-2 | R wave duration in lead III |
| 10004-0 | R wave duration in lead V1 |
| 10005-7 | R wave duration in lead V2 |
| 10006-5 | R wave duration in lead V3 |
| 10007-3 | R wave duration in lead V4 |
| 10008-1 | R wave duration in lead V5 |
| 10009-9 | R wave duration in lead V6 |
| 100182-5 | Duration of standing before sitting due to knee discomfort (qualitative) |
| 100183-3 | Duration of walking before stopping due to knee discomfort (qualitative) |
| 10022-2 | R' wave duration in lead AVF |
| 10023-0 | R' wave duration in lead AVL |
| 10024-8 | R' wave duration in lead AVR |
| 10025-5 | R' wave duration in lead I |
| 10026-3 | R' wave duration in lead II |
| 10027-1 | R' wave duration in lead III |
| 10028-9 | R' wave duration in lead V1 |
| 10029-7 | R' wave duration in lead V2 |
| 10030-5 | R' wave duration in lead V3 |
| 10031-3 | R' wave duration in lead V4 |
| 10032-1 | R' wave duration in lead V5 |
| 10033-9 | R' wave duration in lead V6 |
| 100346-6 | Clotting time (Blood, thromboelastography.rotational.extrinsic coagulation system activated.platelets inhibited) |
| 100347-4 | Clot formation (Blood, thromboelastography.rotational.extrinsic coagulation system activated.platelets inhibited) |
| 10046-1 | S wave duration in lead AVF |
| 10047-9 | S wave duration in lead AVL |
| 10048-7 | S wave duration in lead AVR |
| 10049-5 | S wave duration in lead I |
| 10050-3 | S wave duration in lead II |
| 10051-1 | S wave duration in lead III |
| 10052-9 | S wave duration in lead V1 |
| 10053-7 | S wave duration in lead V2 |
| 10054-5 | S wave duration in lead V3 |
| 10055-2 | S wave duration in lead V4 |
| 10056-0 | S wave duration in lead V5 |
| 10057-8 | S wave duration in lead V6 |
| 10070-1 | S' wave duration in lead AVF |
| 10071-9 | S' wave duration in lead AVL |
| 10072-7 | S' wave duration in lead AVR |
| 10073-5 | S' wave duration in lead I |
| 10074-3 | S' wave duration in lead II |
| 10075-0 | S' wave duration in lead III |
| 100758-2 | Estimated lung age (based on clinical data) |
| 10076-8 | S' wave duration in lead V1 |
| 10077-6 | S' wave duration in lead V2 |
| 10078-4 | S' wave duration in lead V3 |
| 10079-2 | S' wave duration in lead V4 |
| 10080-0 | S' wave duration in lead V5 |
| 10081-8 | S' wave duration in lead V6 |
| 101691-4 | Duration of physical activity |
| 101693-0 | Duration of light heart rate zone |
| 101694-8 | Duration of moderate heart rate zone |
| 101695-5 | Duration of intense heart rate zone |
| 101997-5 | Clot initiation.kaolin induced (Blood, thromboelastography) |
| 101998-3 | Clot formation.kaolin induced (Blood, thromboelastography) |
| 102001-5 | Clot initiation.kaolin induced (Blood, thromboelastography^after addition of heparinase) |
| 102002-3 | Clot formation.kaolin induced (Blood, thromboelastography^after addition of heparinase) |
| 10214-5 | Surgical operation note anesthesia duration |
| 10220-2 | Surgical operation note prep time duration |
| 103206-9 | Duration of workout pause |
| 103210-1 | Awakening duration |
| 103212-7 | Duration of falling asleep |
| 103220-0 | Duration of snoring |
| 103619-3 | Coagulation surface induced.lupus sensitive.buffer (LA control) in Platelet poor plasma (coagulation assay) |
| 103745-6 | Time interval between troponin I.high-sensitivity assays |
| 103931-2 | How many hours per day have you spent on social media platforms over the past 2 weeks |
| 103932-0 | How many hours per day have you spent watching news on television over the past 2 weeks |
| 103933-8 | How many hours per day have you spent speaking with friends or family over the past 2 weeks |
| 103934-6 | How many hours per day have you spent on streaming platforms over the past 2 weeks |
| 103973-4 | Paternal age at fetal death |
| 104047-6 | 10-meter walking distance |
| 104187-0 | Disease onset to death interval duration |
| 104719-0 | Direction repetition timing |
| 104787-7 | Medication duration completed Reporting Period Medication Narrative |
| 104790-1 | Medication maximum dose allowed period Medication |
| 104793-5 | Therapeutic direction duration |
| 104888-3 | Duration of reaction |
| 104905-5 | Duration of exposure |
| 105256-2 | Longest amount of time family members spent in jail or prison (qualitative) |
| 105356-0 | Number of days having an air quality index value (AQI) |
| 105357-8 | Number of days having an AQI value 0 through 50 |
| 105358-6 | Number of days having an AQI value 51 through 100 |
| 105361-0 | Number of days carbon monoxide |
| 105362-8 | Number of days nitrogen dioxide |
| 105363-6 | Number of days ozone |
| 105364-4 | Number of days having an AQI value 101 through 150 |
| 105365-1 | Number of days having an AQI value 151 through 200 |
| 105366-9 | Number of days having an AQI value 201 or higher |
| 105368-5 | Number of days sulphur dioxide |
| 105369-3 | Number of days particulate matter2.5 |
| 105370-1 | Number of days particulate matter10 |
| 105509-4 | Age at which you began taking medicine for this |
| 105520-1 | At what age did you begin taking medicine for this |
| 10572-6 | Duration^post ejaculation |
| 10580-9 | Liquefaction (Semen) |
| 105837-9 | Were lipemic specimens clarified (centrifugation at about 15,000g prior to testing) |
| 10587-4 | Sexual abstinence duration |
| 106175-3 | Condition Duration |